Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. - Wikidata - wikimedia - TriplyDB

Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases.

Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases.

http://www.wikidata.org/entity/Q37254885

about

Genome-editing Technologies for Gene and Cell Therapy Application of CRISPR/Cas9 Technology to HBV Image-Guided Hydrodynamic Gene Delivery: Current Status and Future Directions Progress and Prospects of Anti-HBV Gene Therapy Development Progress and prospects of engineered sequence-specific DNA modulating technologies for the management of liver diseases Capsid-Targeted Viral Inactivation: A Novel Tactic for Inhibiting Replication in Viral Infections Genome editing: the road of CRISPR/Cas9 from bench to clinic Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA Therapeutic genome editing: prospects and challenges Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment TALEN based HPV-E7 editing triggers necrotic cell death in cervical cancer cells Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance.TALEN and CRISPR/Cas Genome Editing Systems: Tools of Discovery.The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo Damaging the Integrated HIV Proviral DNA with TALENs.CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus Hepatitis B virus: new therapeutic perspectives.Genome editing and the next generation of antiviral therapy.Targeting Hepatitis B Virus With CRISPR/Cas9.Synthetic biology for therapeutic applications.AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication Model systems of motor neuron diseases as a platform for studying pathogenic mechanisms and searching for therapeutic agents.Search for a cure for chronic hepatitis B infection: How close are we?Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy.Generation of TALE nickase-mediated gene-targeted cows expressing human serum albumin in mammary glands.Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus.An alternative novel tool for DNA editing without target sequence limitation: the structure-guided nuclease The Development of TALE Nucleases for Biotechnology.Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9.DNA cleavage enzymes for treatment of persistent viral infections: recent advances and the pathway forward.A guide to genome engineering with programmable nucleases.Applications of TALENs and CRISPR/Cas9 in human cells and their potentials for gene therapy.Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure.Gene therapeutic approaches to inhibit hepatitis B virus replication.Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.Advances in therapeutics for chronic hepatitis B.Therapeutic strategies for a functional cure of chronic hepatitis B virus infection.From hacking the human genome to editing organs The state of gene therapy research in Africa, its significance and implications for the future.Programmable Site-Specific Nucleases for Targeted Genome Engineering in Higher Eukaryotes.

P2860

Q26769662-9402498E-ED84-45A8-B126-83123899CAA8 Q26779150-9F3325E9-9A34-48B9-842C-C9E5E4AD69D6 Q26797323-3D8F9868-43C9-4BD8-B79F-DE24B91F1A18 Q26799228-CD5A0FD6-14E0-4386-A0D7-98E3A63E3CC0 Q27011249-F0696342-AB0F-4080-90CF-60AEA5FAE89B Q27468669-4C6E97EB-1CA7-478D-AE42-AC192DDA4694 Q28066970-F3C93151-074D-4862-857D-280B26E2CBDF Q28081274-1CE52B8A-EAE2-48FF-9C39-177AB5B23498 Q28087380-26997905-360F-4307-B451-1306B713B151 Q28087526-9CC92D65-E628-4006-9947-DA99C5524180 Q33905878-37405CC4-0FD7-4830-AC2A-B7D4BBB9005A Q34289969-ADE5F5B2-36AF-4641-A71C-256CBA6CE4D5 Q34394269-729C1480-1A67-47C5-9D2F-44D5145D3D19 Q34459390-9724942A-F4BC-4173-AF6D-8D5D8B72CE12 Q34475249-144FC901-6FBE-4F1F-8F86-74B70AC9658A Q34478938-5D08EA0D-BC1B-4175-B774-01B4078E3294 Q34507250-48651D3B-FD30-42F4-84F4-6B4A60F50BB9 Q34529971-5FB4AF14-0560-457A-ADF5-CBA9CF27B9A7 Q34745348-11FE4505-581F-4BA5-B04C-00AC32ACE143 Q35057524-BB2EDFA9-4352-45CE-87ED-10233F8BCE10 Q35168444-3FC5071C-DB6F-417D-B639-52C7B137E3D4 Q35540393-7493C628-CB81-4EA7-A28A-9CD9076EED8A Q35626790-7229545D-5EC3-40AF-8686-0A86BFD122C2 Q36494284-2E92DBD8-3024-4A9D-AB29-4F3D5CDE61F8 Q36555642-ABD661A0-A5AF-4D70-A4A2-D11F1BA09EDB Q36951290-BF6347AE-90E4-4BDE-A0DF-021BB14BE5EA Q37260380-BF365CED-D33C-4469-B2F6-1A2CB218780F Q37652116-0CB09906-8B00-4985-88A1-69D72B569B98 Q37714431-6937DABA-5392-4AC7-97E1-639605E0611A Q38184158-05ED6770-A104-47EC-A37F-38D4D5A72995 Q38201212-3FD8382B-C505-4CD8-B599-4DF04F6EA9E1 Q38215595-14906B84-0210-4EC0-968B-D1B97BFB52BC Q38351585-F37E2E95-9770-4048-BDA7-0A7FC12029DD Q38366585-860500AB-936D-49A7-B5DE-0BB219CE8EFA Q38566445-2594CEB0-DBF9-492B-A60D-511A670CF3B6 Q38585657-41412BEF-E605-4D2C-9AAC-E947411C262B Q38636988-B1E71D7B-61B3-4C16-BA45-3E3A73CDB25E Q38640256-42CF10D1-B273-4E32-B66E-EFA3DC72D393 Q38660339-FB08F3CC-71E0-4C3B-825E-9D144ABDAAA7 Q38761853-046BD236-B07E-42D5-AC3F-B9C102E9F2F6

P2860

Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases.

http://www.wikidata.org/entity/Q37254885

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Inactivation of hepatitis B vi ...... vator-like effector nucleases.

@en

Inactivation of hepatitis B vi ...... vator-like effector nucleases.

@nl

type

label

Inactivation of hepatitis B vi ...... vator-like effector nucleases.

@en

Inactivation of hepatitis B vi ...... vator-like effector nucleases.

@nl

prefLabel

Inactivation of hepatitis B vi ...... vator-like effector nucleases.

@en

Inactivation of hepatitis B vi ...... vator-like effector nucleases.

@nl

P1433

Q37254885-EE3C17CC-18DC-4DF9-93EF-AC5511544B1A

P1476

Q37254885-DB68DF0B-7A5C-44B9-AA90-4BD952BB0519

P2093

Q37254885-6D2A315B-3B1D-4881-BBBB-96CCBE65548A

Q37254885-BDA51206-82D8-4B7E-90E6-1AD01025CB0A

Q37254885-E8B45087-4C22-4DD0-A0C8-9E8B0C35DBCC

Q37254885-FFC76479-0F33-4345-96E9-4912AB6C6995

P2860

Q37254885-002277F0-A118-453C-8E35-619592E5B233

Q37254885-0385D608-7367-4C1A-B855-9BEFA8B3D7BE

Q37254885-04C66BD2-0FEC-4C98-8F14-7E0D3B0CE621

Q37254885-07AD8961-7C36-41E5-82C6-C15A6BD074BC

Q37254885-092CED09-0AD7-4935-95C7-5EBDAAC25780

Q37254885-09300AAA-4083-4848-B24E-E25AEB7C48E1

Q37254885-0D34F12B-A0E0-4A6C-A5EE-C0E3E8FBFBC8

Q37254885-0F9363B3-C2F4-4EE1-91A7-637810EC14D5

Q37254885-1D1B7D75-E0B6-4022-9F47-29B46EC145E8

Q37254885-1F3869E2-47BC-4990-A6A7-7F90D5721565

P304

Q37254885-E8BC9721-2BEC-4083-93B1-62E8FFF790C7

P31

Q37254885-A8D3BB49-4988-4CF1-A4C5-E1561093A11E

P356

Q37254885-A5E69A95-9D4B-4095-8691-3601EF34170C

P433

Q37254885-3F3C16B7-CCAB-4F59-9CA6-B0E8CEE5D75E

P478

Q37254885-6D138F5D-8932-4C76-93E1-36225E7553E8

P50

Q37254885-B19E9A6E-AC9F-4C64-BE99-617C715E987D

P577

Q37254885-86966C04-5C27-49D3-95CE-7EFDDD83A4A8

P5875

Q37254885-27E1B8D4-0700-48FC-8A6B-AFEA8ECE03AB

P698

Q37254885-E43AA8F4-77F6-46A6-9A12-B65A2CE02E49

P932

Q37254885-BB93060B-9470-42DA-B9E9-4C41B0BA2720

P356

P1433

Molecular Therapy

P1476

Inactivation of hepatitis B vi ...... ivator-like effector nucleases

@en

P2093

Abdullah Ely

http://www.w3.org/2001/XMLSchema#string

Claudio Mussolino

http://www.w3.org/2001/XMLSchema#string

Kristie Bloom

http://www.w3.org/2001/XMLSchema#string

Patrick Arbuthnot

http://www.w3.org/2001/XMLSchema#string

P2860

Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain

Multiplex genome engineering using CRISPR/Cas systems

Efficient genome editing in zebrafish using a CRISPR-Cas system

Targeted DNA mutagenesis for the cure of chronic viral infections

High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

Epidemiology of viral hepatitis and hepatocellular carcinoma

Homing endonucleases: structure, function and evolution.

Putative role of hepatitis B virus X protein in hepatocarcinogenesis: effects on apoptosis, DNA repair, mitogen-activated protein kinase and JAK/STAT pathways.

Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs.

P304

1889-1897

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2013.170

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

251877947

http://www.w3.org/2001/XMLSchema#string

P698

23883864

http://www.w3.org/2001/XMLSchema#string

P932

3808145

http://www.w3.org/2001/XMLSchema#string